成大生物12月23日获融资买入422.49万元，融资余额2.70亿元

Group 1 - The core viewpoint of the news is that Chengda Biological experienced a decline in stock price and trading volume, with significant financing activities indicating high investor interest despite recent financial challenges [1][2]. Group 2 - On December 23, Chengda Biological's stock fell by 0.84%, with a trading volume of 32.51 million yuan. The financing buy-in amount was 4.22 million yuan, while the financing repayment was 2.56 million yuan, resulting in a net financing buy of 1.67 million yuan [1]. - As of December 23, the total balance of margin trading for Chengda Biological was 272 million yuan, with the financing balance accounting for 2.51% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, on December 23, 5,971 shares were repaid, and 1,200 shares were sold short, with a selling amount of 31,100 yuan. The remaining short-selling volume was 43,300 shares, with a balance of 1.12 million yuan, also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Biological was 24,300, a decrease of 4.17% from the previous period, while the average circulating shares per person increased by 4.36% to 17,147 shares [2]. - For the period from January to September 2025, Chengda Biological reported operating revenue of 1.096 billion yuan, a year-on-year decrease of 15.88%, and a net profit attributable to shareholders of 165 million yuan, down 50.01% year-on-year [2]. - Since its A-share listing, Chengda Biological has distributed a total of 1.492 billion yuan in dividends, with 1.075 billion yuan distributed over the past three years [2]. Group 4 - As of September 30, among the top ten circulating shareholders, Hong Kong Central Clearing Limited was the fourth largest with 1.9124 million shares, an increase of 9,100 shares from the previous period. Meanwhile, Southern CSI 1000 ETF held 1.9011 million shares, a decrease of 7,600 shares [2].